Tag: adalimumab
ABBV-3373: A potential new therapeutic agent for RA
Similar efficacy of ustekinumab and adalimumab for moderate-to-severe CD
Risk of hospitalisation and surgery linked to IBD biological
Obesity increases the risk of immunogenicity to adalimumab in IBD
Adalimumab added to methotrexate yields better results in PsA than methotrexate escalatio
Upadacitinib provides fast onset of improvement in psoriatic arthritis
Secukinumab monotherapy as efficient as adalimumab
Biologics in HS – a growing armamentarium
Biologic psoriasis treatment to lower cardiovascular risk?
Effects of vedolizumab versus adalimumab on QoL
Vedolizumab and anti-TNF therapies: a real-world comparison
Vedolizumab, adalimumab, and golimumab compared
High versus standard adalimumab in active UC
TNFi for RA during pregnancy – to stop or not to stop?
Biologics: increasingly used in paediatric dermatology
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Switching upadacitinib and adalimumab is beneficial in refractory RA
Efficacy and safety of ixekizumab versus adalimumab in patients with PsA
Switch to sarilumab from adalimumab is efficacious and safe
Adalimumab vs adalimumab + methotrexate in psoriasis: First-year results on effectiveness, drug survival, safety, and immunogenicity
ABP501 biosimilar for adalimumab: What you need to know
Vedolizumab superior to adalimumab in ulcerative colitis
Proactive adalimumab trough measurements
Biologic drug levels and infection risk, and clinical effectiveness of sarilumab
